Waldencast plc operates as a global multi-brand beauty and wellness platform built around Obagi Medical and Milk Makeup. News about WALD commonly covers brand-level product launches, physician-dispensed skincare, cosmetics, suncare, and aesthetic offerings, including Obagi's advanced skincare products and Obagi® saypha® MagIQ™ hyaluronic acid filler.
Company updates also include quarterly and annual financial results, segment performance, channel and distribution developments, clinical-evidence collaborations for aesthetic products, supply-chain and credit-facility actions, and governance or reporting matters tied to financial restatements, internal control over financial reporting, and regulatory review.
Waldencast (NASDAQ: WALD) announced on April 28, 2026 that the SEC has concluded its investigation related to Waldencast's restatement and historical accounting practices at Obagi Cosmeceuticals.
Based on available information, the SEC does not intend to recommend enforcement action. The company said it fully cooperated and incurred substantial legal and advisory costs.
Obagi Medical (NASDAQ: WALD) launched NU-GEN™ Cellular Renewal Serum on March 24, 2026, a 1oz/30ml topical formula priced at $175 that pairs NAD+ with NMN and niacinamide to address nine visible signs of skin aging.
Clinical results cited include up to six years of visible age reversal, 51% improvement in tone evenness, 30% reduction in fine lines, and rapid hydration gains within 30 minutes.
Obagi Medical (NASDAQ: WALD) announced a collaboration with ProMD Health on March 19, 2026 to enroll ProMD’s multi-location network in the ALOHA Program to evaluate Obagi® saypha® MagIQ™ in real-world practice. The program will use standardized data collection across 17 ProMD locations and combine Obagi clinical education with ProMD injector experience to assess clinical efficacy, patient experience, and integrated post-care protocols, contributing to growing real-world evidence for MagIQ’s performance in diverse aesthetic settings.
Waldencast (NASDAQ: WALD) reported FY2025 net revenue of $272.1M (flat YoY) and Q4 2025 net revenue of $72.0M. Adjusted EBITDA was $16.1M for FY2025 and $6.6M for Q4. The company completed the sale of Obagi Japan for $82.5M and refinanced with a $225M three-year credit facility, lowering net debt to $121.7M.
Obagi Medical grew, including FDA approval and acquisition activity tied to injectables; Milk Makeup saw U.S. gains but softer international sales.
Waldencast (NASDAQ: WALD) said it will release Fourth Quarter and Fiscal Year 2025 results on March 13, 2026 before U.S. market open. The company also said it will not host a conference call to discuss results due to its ongoing strategic review.
Obagi Medical (NASDAQ: WALD) announced a collaboration with Schweiger Dermatology to run the ALOHA Program, launching a Phase 4 clinical study and a real-world evaluation to generate post‑approval evidence for Obagi® saypha® MagIQ™. Initial activities are expected to begin in early 2026.
The program aims to translate pivotal trial safety and efficacy into everyday practice across Schweiger’s national network and present findings internally and at industry conferences.
Obagi Medical (NASDAQ: WALD) announced a collaboration with It’s a Secret Med Spa on Feb 25, 2026 to enroll premium med spa locations in the ALOHA real-world program evaluating saypha® MagIQ™. The program will capture standardized real-world data across participating sites and integrate Obagi protocols.
It’s a Secret brings 15 high-end locations and luxury clinical experience to support evaluation and patient outcomes.
Obagi Medical (NASDAQ: WALD) announced a collaboration with Aesthetic Record to run the ALOHA Real-World Program for Obagi® saypha® MagIQ™, aiming to translate FDA pivotal trial results into everyday practice across multiple providers.
The program leverages Aesthetic Record’s EMR platform used by over 9,000 clinics to capture standardized clinical data, run structured evaluations, and present initial findings at industry conferences.
Obagi Medical (NASDAQ: WALD) announced a collaboration with DermFx to run the ALOHA Real-World Program for Obagi® saypha® MagIQ™, aiming to translate FDA pivotal trial results into routine med spa practice. The program will use standardized data capture across DermFx’s five Southern California locations and present initial findings internally.
The partnership emphasizes evidence-based rollout, provider training, integrated skincare-injectable protocols, and support for regional practices to evaluate patient outcomes and satisfaction.
Obagi Medical (NASDAQ: WALD) announced a strategic collaboration with Moxie to run the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program, a real-world evidence initiative evaluating saypha MagIQ across Moxie-supported aesthetic practices. Standardized data collection and early results will be shared at industry events.